Peptides in sexual medicine: evidence

A 2026 narrative review found a narrow evidence base for peptides in urology and sexual medicine. Among the agents it assessed, bremelanotide has an approved sexual-medicine indication in the United States, while kisspeptin has early randomized human data. CJC-1295 and several other growth hormone secretagogues have not shown that raising hormone concentrations improves sexual function^[1]. The distinction between a measured biological effect and a useful treatment runs through the whole review.

What the review covered

The authors searched three literature databases for work on bremelanotide, melanotan II, kisspeptin, oxytocin, PnPP-19, gonadorelin, growth hormone secretagogues, and related compounds. The secretagogue group included GHRP-2, GHRP-6, ibutamoren, ipamorelin, tesamorelin, sermorelin, and CJC-1295. Study designs and populations differed, as did outcome measures, so the authors could not calculate a pooled estimate and used a narrative synthesis^[1]. This is a map of uneven evidence, not a trial comparing all of the compounds with one another.

The mechanisms also differ. Bremelanotide acts through melanocortin receptors involved in desire and arousal. Kisspeptin influences reproductive signaling as well as brain responses to sexual cues. Growth hormone secretagogues stimulate the growth hormone axis. Oxytocin has a plausible role in sexual response and bonding, while PnPP-19 remains in preclinical development. Grouping them under the word peptide does not make their clinical evidence interchangeable.

Bremelanotide has the clearest clinical case

The two RECONNECT phase 3 trials randomized 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compared with placebo over 24 weeks, bremelanotide produced statistically significant improvements in sexual-desire scores and reductions in distress related to low desire. Nausea and flushing occurred more often with bremelanotide, as did headache^[2]. These outcomes support one diagnosis in a specific population. They do not establish efficacy for erectile dysfunction, infertility, postmenopausal low desire, or general sexual enhancement. The trials also measured changes on symptom scales rather than proving that every participant experienced a personally meaningful benefit.

The US label for bremelanotide specifies a 1.75 mg subcutaneous dose used as needed at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month. This is label reporting, not a recommendation. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease, warns about temporary blood-pressure increases, and notes focal hyperpigmentation and nausea^[3]. The prescribing information also directs discontinuation after eight weeks if symptoms have not improved. A clinician has to decide whether the approved indication and those risks fit an individual patient.

Kisspeptin is promising but investigational

A randomized, double-blind crossover trial enrolled 37 men with hypoactive sexual desire disorder, of whom 32 completed the study. During a 75-minute intravenous infusion, kisspeptin-54 changed activity in brain regions involved in sexual processing. Secondary analyses found greater penile tumescence in response to sexual videos and improved scores on some behavioral measures compared with placebo^[4]. The experiment provides a human signal, but it was conducted at one center, tested an acute infusion, and did not measure sustained symptom improvement in routine care.

Kisspeptin therefore sits at an earlier stage than bremelanotide. The trial helps explain a possible mechanism and supports further testing. It does not supply an approved regimen or long-term safety profile. Nor does it show that products sold online contain the studied compound at a reliable concentration. The review describes kisspeptin as investigational and calls for standardized dosing and longer follow-up.

Hormone changes are not sexual outcomes

The growth hormone section needs the most restraint. In a randomized study of healthy adults, CJC-1295 produced sustained increases in growth hormone and insulin-like growth factor 1 after single or repeated injections^[5]. That pharmacodynamic result shows that the compound affected its target pathway. It did not show improved erectile function, sexual desire, physical performance, quality of life, or patient satisfaction. The 2026 review reaches the same broader conclusion for growth hormone secretagogues: hormone concentrations rise reliably, but evidence for meaningful sexual or performance outcomes remains limited^[1].

Tesamorelin illustrates another common category error. It is an approved medicine in the United States for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its FDA label does not establish a sexual-medicine indication, and it warns about elevated insulin-like growth factor 1, fluid retention, glucose intolerance, and malignancy-related precautions^[6]. Readers can review the separate tesamorelin evidence page, but approval for one condition should not be borrowed to support another.

What remains unknown

The review identifies recurring limits. Samples are often small, follow-up is short, and outcome measures vary. Cardiovascular and metabolic safety need better assessment, as does possible cancer risk. Evidence for oxytocin is limited despite a plausible mechanism. PnPP-19 remains preclinical. Melanotan II, ibutamoren, CJC-1295, and related products are sold through unregulated channels even though product identity, dose consistency, and adverse effects may be uncertain.

The practical readout is selective rather than class-wide. Bremelanotide has evidence and a label for a defined group of premenopausal women. Kisspeptin has an interesting short-term human experiment that needs longer clinical trials. For growth hormone secretagogues, a rise in laboratory hormone values cannot stand in for a patient-centered sexual outcome. None of these papers authenticate a vial sold as a research chemical, and trial doses should not be treated as instructions for unsupervised use.